# Veterinary biotech & mRNA veterinary drugs

Advanced veterinary biotechnology focusing on mRNA vaccines, recombinant proteins, and novel biologics to combat zoonotic and livestock diseases with rapid-response platforms.

Source: https://en.bioecon.ru/technology/veterinary-biotech-mrna-drugs/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: Regulation (EU) 2019/6 | OECD: biotech-health | Regulator: USDA (USA), EMA (EU)]

Veterinary biotechnology leverages advanced genetic engineering, mRNA platforms, and recombinant protein expression to develop next-generation vaccines and therapeutics for companion animals and livestock. Driven by the need to combat zoonotic spillovers, African Swine Fever (ASF), and avian influenza, these platforms enable rapid sequence-to-vaccine timelines—sometimes under 8 weeks. With over 70% of new human infectious diseases originating in animals, the sector integrates One Health principles, prioritizing rapid-response RNA particle technology, lipid nanoparticle (LNP) delivery, and scalable cell-culture manufacturing to ensure global food security and animal welfare.

The key directions of veterinary biotech are:
1. **mRNA and RNA particle vaccines:** Delivers pathogen-specific genetic sequences directly into cells, eliciting robust immune responses without using live viruses.
2. **Recombinant protein therapeutics:** Engineered monoclonal antibodies for companion animal chronic diseases, such as osteoarthritis and atopic dermatitis.
3. **Viral vector platforms:** Utilizes harmless carrier viruses to present specific antigens to the animal's immune system, offering stable, single-dose protection.
4. **Diagnostic biomarkers:** Advanced molecular diagnostics and point-of-care PCR tests for real-time herd health monitoring and outbreak containment.

### Sectoral value chain

```
[Pathogen genomics] ──> [Antigen design] ──> [Biomanufacturing] ──> [Formulation]
                                                 │
                                           (LNP/Adjuvants)
                                                 │
                                                 ▼
[Herd immunity] <─── [Veterinary delivery] <─────┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Pathogen genomics** | Sequencing and analyzing emerging viral or bacterial strains. | **In:** Field samples.<br>**Out:** Target genetic sequences. |
| **Antigen design** | Engineering mRNA constructs or recombinant plasmids for immunity. | **In:** Target genetic sequences.<br>**Out:** Candidate constructs. |
| **Biomanufacturing** | Large-scale cell culture or cell-free transcription of the active biologic. | **In:** Candidate constructs.<br>**Out:** Bulk drug substance. |
| **Formulation** | Encapsulation in LNPs or mixing with veterinary adjuvants for stability. | **In:** Bulk drug substance.<br>**Out:** Final vaccine/therapeutic. |
| **Regulatory trials** | Efficacy and safety testing in target species under USDA/EMA oversight. | **In:** Final vaccine/therapeutic.<br>**Out:** Approved veterinary biologic. |
| **Veterinary delivery** | Administration via injection, feed, or aerosolized spray to animals. | **In:** Approved veterinary biologic.<br>**Out:** Protected livestock/pets. |

Cross-cutting technologies of the sector:
- **Lipid nanoparticle (LNP) delivery:** Ensures mRNA stability in non-human physiological conditions.
- **Microfluidic encapsulation:** Scalable systems for mixing mRNA with lipid matrices.
- **Cold-chain logistics:** Specialized supply chains for thermolabile veterinary biologics.

---

## US

The US market leads in the rapid authorization and deployment of RNA-based veterinary biologics, largely driven by USDA's progressive regulatory pathways and massive livestock industries.

### Rapid-response vaccines, Companion animal therapeutics, Swine health
- **Sequivity RNA platforms:** USDA-approved custom swine vaccines developed from sequence to farm in weeks.
- **Companion animal biologics:** High adoption of monoclonal antibodies for canine and feline chronic conditions.
- **Avian influenza preparedness:** Heavy investment in mRNA vaccine stockpiles for poultry following widespread highly pathogenic avian influenza (HPAI) outbreaks.

---

## CN

China prioritizes veterinary biotech as a matter of national food security, investing heavily in recombinant and mRNA vaccines to protect its massive swine and poultry populations.

### Swine disease control, High-throughput manufacturing, Food security
- **African Swine Fever (ASF) vaccines:** National push for advanced biologics to mitigate devastating economic losses in the pork industry.
- **State-backed mega-facilities:** Construction of high-capacity biosafety level 3 (BSL-3) manufacturing plants for veterinary biologics.
- **Rapid commercialization:** Accelerated regulatory tracks by the MoA for vaccines targeting economically critical livestock diseases.

---

## EU

The EU emphasizes a One Health approach, focusing on reducing antimicrobial resistance (AMR) in livestock through advanced prophylactic vaccines and strict regulatory oversight.

### AMR reduction, One Health framework, Stringent regulation
- **Phasing out antibiotics:** Strong regulatory pressure to replace prophylactic antibiotics with next-generation vaccines in farming.
- **Centralized EMA approvals:** Harmonized, rigorous authorization pathways for novel veterinary therapies across member states.
- **Zoonotic disease monitoring:** Cross-border integration of veterinary diagnostics and human health surveillance systems.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Zoetis** | 🇺🇸 USA | *Cytopoint, Apoquel, Vaccines* | Recombinant mAbs, viral vectors | commercial |
| **Boehringer Ingelheim** | 🇩🇪 Germany | *Ingelvac, NexGard* | Recombinant vaccines, adjuvants | commercial |
| **MSD Animal Health** | 🇳🇱 Netherlands | *Sequivity RNA particles* | Custom RNA replicon vaccines | commercial |
| **Genvax Technologies** | 🇺🇸 USA | *Animal mRNA vaccines* | self-amplifying mRNA (saRNA) | operating |
| **Hester Biosciences** | 🇮🇳 India | *Poultry and large animal vaccines* | Live attenuated, recombinant | commercial |
| **Jinyu Bio-technology** | 🇨🇳 China | *FMD and ASF vaccines* | Cell-suspension culture | commercial |

---

## Tech stack and innovations

Modern veterinary biologics rely heavily on cell-free synthesis, advanced delivery vehicles, and precision immunology to bypass traditional egg-based or live-attenuated production constraints.

1. **Self-amplifying mRNA (saRNA):**
   - Engineered RNA constructs that replicate their antigen-encoding sequences upon entering host cells.
   - Allows for microgram-level dosing (e.g., 1–5 µg per dose), significantly reducing the cost per animal compared to conventional mRNA.
2. **RNA Particle Technology (e.g., Sequivity):**
   - Uses a non-replicating alphavirus backbone to deliver genetic instructions directly to dendritic cells.
   - Requires only a digital sequence of the pathogen, bypassing the need to culture live dangerous viruses in biosafety facilities.
3. **Monoclonal Antibodies (mAbs) for Companion Animals:**
   - Species-specific (caninized or felinized) antibodies developed via recombinant DNA technology.
   - Targets specific interleukins (e.g., IL-31 for itch) with a half-life permitting monthly dosing.

---

## Value chains and production pipelines

### Industrial pipeline of veterinary mRNA vaccine manufacturing (cGMP)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Plasmid DNA production │ ───> │ 2. In vitro transcription │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. LNP encapsulation      │ <─── │ 3. mRNA purification    │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Sterile fill and finish│ ───> │ 6. Cold-chain storage     │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Plasmid DNA production
E. coli fermentation is used to amplify plasmid DNA containing the target antigen sequence, which is then purified and linearized to serve as a template.

#### Stage 2: In vitro transcription
The linearized DNA template is mixed with RNA polymerase and nucleotide triphosphates (NTPs) in a cell-free bioreactor to synthesize the mRNA strands.

#### Stage 3: mRNA purification
Chromatographic techniques (such as affinity or ion-exchange chromatography) remove residual DNA templates, enzymes, and truncated RNA fragments to yield highly pure mRNA.

#### Stage 4: LNP encapsulation
The purified mRNA is combined with a precise mixture of ionizable lipids, cholesterol, and PEG-lipids in microfluidic mixers to form stable lipid nanoparticles.

#### Stage 5: Sterile fill and finish
The LNP-formulated vaccine undergoes tangential flow filtration for buffer exchange, followed by sterile filtration and automated filling into veterinary multi-dose vials.

#### Stage 6: Cold-chain storage
Vials are visually inspected, labeled, and placed in ultra-low temperature freezers or standard refrigeration (depending on lipid stability) for distribution to farms and clinics.

---